Esperion Therapeutics (ESPR) Share-based Compensation (2012 - 2026)

Esperion Therapeutics has reported Share-based Compensation for 15 years, with the latest figure at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 1.5% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $9.9 million (down 11.73% YoY), and the FY2025 full-year result was $9.9 million, down 17.7% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.5 million, up from $2.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $4.4 million in Q1 2022, with the low at $2.3 million in Q3 2025.
• Historically, Share-based Compensation has averaged $3.0 million across 5 years, with a median of $2.9 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation plunged 58.91% — and 2024, when it increased 11.44%.
• Esperion Therapeutics' Share-based Compensation stood at $3.7 million in 2022, then slipped by 21.4% to $2.9 million in 2023, then decreased by 3.94% to $2.8 million in 2024, then dropped by 14.9% to $2.4 million in 2025, then grew by 4.82% to $2.5 million in 2026.
• The last three Share-based Compensation figures came in at $2.5 million (Q1 2026), $2.4 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.